165 related articles for article (PubMed ID: 28092671)
1. PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
Delyon J; Servy A; Laugier F; André J; Ortonne N; Battistella M; Mourah S; Bensussan A; Lebbé C; Dumaz N
Oncogene; 2017 Jun; 36(23):3252-3262. PubMed ID: 28092671
[TBL] [Abstract][Full Text] [Related]
2. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.
Marquette A; André J; Bagot M; Bensussan A; Dumaz N
Nat Struct Mol Biol; 2011 May; 18(5):584-91. PubMed ID: 21478863
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
4. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R
Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
Gaggioli C; Robert G; Bertolotto C; Bailet O; Abbe P; Spadafora A; Bahadoran P; Ortonne JP; Baron V; Ballotti R; Tartare-Deckert S
J Invest Dermatol; 2007 Feb; 127(2):400-10. PubMed ID: 16960555
[TBL] [Abstract][Full Text] [Related]
8. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
[TBL] [Abstract][Full Text] [Related]
9. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.
Sumimoto H; Miyagishi M; Miyoshi H; Yamagata S; Shimizu A; Taira K; Kawakami Y
Oncogene; 2004 Aug; 23(36):6031-9. PubMed ID: 15208655
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
12. Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts.
Bruss MD; Richter W; Horner K; Jin SL; Conti M
J Biol Chem; 2008 Aug; 283(33):22430-42. PubMed ID: 18508768
[TBL] [Abstract][Full Text] [Related]
13. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
14. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
15. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J
Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897
[TBL] [Abstract][Full Text] [Related]
16. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
17. PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways.
Mika D; Conti M
Cell Signal; 2016 Jul; 28(7):719-24. PubMed ID: 26562185
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
19. B-RAF: A contributor to the melanoma phenotype.
Heath EM; Kaufman KL; Christopherson RI
Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.
Arozarena I; Sanchez-Laorden B; Packer L; Hidalgo-Carcedo C; Hayward R; Viros A; Sahai E; Marais R
Cancer Cell; 2011 Jan; 19(1):45-57. PubMed ID: 21215707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
